# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emile Griffith (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX005-SYN-TD
- Date: 2005-09-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Fairbanks-Ochieng, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-month review of PTSD, mood and memory. **S**

## History of present illness

Emile Griffith returns with his care partner. He finished twelve sessions of cognitive processing therapy five weeks ago. He says he no longer blames himself in the same way: he went into the ring to win, not to hurt anyone, and he can now speak about his opponent without dreading the memory. Nightmares come about once a week. He takes sertraline 50 mg each morning without nausea, dizziness or bleeding. He completed ten sessions of physical therapy two weeks ago and does the home exercises most days; he has had no falls. His care partner notices no change in his memory. No thoughts of suicide. **S**

| Element | Detail |
|---|---|
| PCL-5 | 26, from 41 at intake |
| PHQ-9 | 5; item 9 scored 0 |
| Sodium | 137 mmol/L on sertraline 50 mg |
| Nightmares | About once a week |
| Timed Up and Go | 10 seconds |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Psychiatric | Positive | Nightmares about once a week; mood good; no thoughts of suicide |
| Neurological | Positive | Forgetfulness unchanged; no headaches, weakness or tremor |
| Gastrointestinal | Negative | No nausea or diarrhea |
| Musculoskeletal | Negative | No falls; legs feel stronger |

4 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/76 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 73.9 kg; BMI 25.6 kg/m². All vital signs are synthetic.

Sodium: 137 mmol/L; PHQ-9: 5; PCL-5: 26. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 137 mmol/L at this visit **S**
- PHQ-9: 9 at baseline, 5 at this visit **S**
- PCL-5: 41 at baseline, 26 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 128/76 mmHg; pulse 66; weight 73.9 kg |
| Musculoskeletal | Timed Up and Go 10 seconds; tandem walk without a side-step |
| Mental status | Bright and relaxed; speaks about the fight calmly; no psychotic symptoms; denies thoughts of suicide |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Post-traumatic stress disorder, chronic** (F43.12). Clinically meaningful response: PCL-5 26 from 41 (a fall of 15 points) after a full course of cognitive processing therapy and sertraline 50 mg. Sodium normal. No thoughts of suicide. **S**
   - Continue sertraline 50 mg.
   - Booster therapy sessions on request.
   - Safety plan and 988 reviewed.
2. **Mild cognitive impairment** (G31.84). Stable by history; strategies working; balance better after physical therapy. **S**
   - Continue the home exercise program and daily walks.
   - MoCA at the yearly review.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA) | At diagnosis, then yearly, or sooner with change | Up to date | MoCA 22 at intake; no change reported; next at the yearly review |
| Survey | Staging (CDR) and function (ADL and IADL) | At diagnosis, then yearly | Up to date | CDR 0.5 at two weeks; function unchanged |
| Examination | Medicine review for anticholinergic, sedating and fall-risk drugs (Beers) | Every visit | Completed today | Sertraline 50 mg only |
| Survey | Neuropsychiatric symptom screen (apathy, irritability, paranoia, impulsivity) | Every visit | Completed today | No apathy, irritability, paranoia or impulsive behavior |
| Survey | PHQ-9 with suicide-risk review (item 9 and structured questions) | Monthly during acute treatment; every visit during active treatment | Completed today | PHQ-9 5, item 9 scored 0; no thoughts of suicide |
| Survey | PCL-5 | Baseline, then at each chronic-care visit during treatment; response judged after 8 to 12 weeks | Completed today | PCL-5 26: a clinically meaningful 15-point fall |
| Medication safety | Sertraline: nausea, sleep, falls, bleeding, and sodium (SSRIs can lower sodium in older adults) | Two weeks after starting and after each dose change; sodium at those points | Deferred | Deviation: the sodium check ordered for two to four weeks after the increase to 50 mg was not done, because no visit fell then and the lab-only appointment was never scheduled. It was done today, three months after the increase: 137 mmol/L, normal, with no confusion, falls or other sign of low sodium, so no harm is known. Corrective action: a lab-only appointment is now booked automatically with any antidepressant start or dose change |
| Referral | Trauma-focused psychotherapy (cognitive processing therapy) | Weekly, about twelve sessions | Completed today | Twelve sessions completed five weeks ago |
| Examination | Fall risk (Timed Up and Go, gait and balance), STEADI | At diagnosis, yearly, and after any fall | Completed today | Timed Up and Go 10 seconds; no falls |
| Referral | Physical therapy for balance and strength | Once, after a Timed Up and Go above 12 seconds | Completed today | Ten sessions completed two weeks ago; home program continues |
| Self-management | Travel, money and home safety | At diagnosis and each follow-up | Completed today | No episodes of getting lost; shared oversight of bills working |
| Survey | Care partner support and burden (Zarit Burden Interview, narrative) | At diagnosis, then every 6 to 12 months | Up to date | Zarit 14 at the diagnosis visit; his care partner attends the caregiver class; next check at about six months |
| Self-management | Advance care planning | At diagnosis; revisit yearly and at changes | Completed today | Health care agent named and goals recorded at the annual wellness visit six weeks ago; reviewed today without change |
| Examination | Vascular risk factors (blood pressure, weight) | Every visit | Completed today | Blood pressure 128/76 mmHg; weight 73.9 kg |

## Goal progress

- Find the cause of the memory problems and explain it to him in a way he can take in. Outcome by 2005-06-16: Mild cognitive impairment most likely due to traumatic brain injury; explained with his care partner present, at his request, with a written summary. **S**
- A clinically meaningful fall in PTSD symptoms (PCL-5 down at least 10 points) by four months. Outcome by 2005-09-15: PCL-5 from 41 to 26 after cognitive processing therapy and sertraline. **S**
- Nightmares no more than about once a week, with at least six hours of sleep most nights. In progress; target 2005-10-27. **S**
- No falls, with a balance and strength program. In progress; target 2005-10-27. **S**
- Name a health care agent and record his goals of care while he can take part fully. Outcome by 2005-08-04: Health care agent named and goals of care recorded at the annual wellness visit. **S**

## Guideline basis

- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024), Alzheimer's Association (Alzheimers Dement 2025;21(1):e14337)
- VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Depression/Bipolar/Mood Disorders monographs (2026), Aether Forge
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society (Journal of the American Geriatrics Society)
- STEADI (Stopping Elderly Accidents, Deaths and Injuries): Clinical Resources (2024), Centers for Disease Control and Prevention

## Follow-up

- Six-month review in six weeks with PCL-5 and PHQ-9, influenza vaccine and the second zoster dose. Call the clinic or 988 at any time if thoughts of suicide arise. **S**
- Next scheduled visit 2005-10-27: six-month review: PTSD, mood, cognition, safety and the plan for the year ahead. **S**
